2 active not recruiting, 2 recruiting, 1 completed, 1 terminated. 4 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow IMC-001: new trials by email Literature Review of IMC-001 trials Research Report on IMC-001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. IMC-001 and Optimal medical treatment, IMC-001 placebo and optimal medical treatment - Atherosclerosis | Early Phase 1 | Recruiting | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 18 | 2025-03-10 | 2026-04-15 |
| A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor IMC-001 - TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors | Phase 2 | Recruiting | ImmuneOncia Therapeutics Inc. | 30 | 2025-01-13 | 2026-04-17 |
| A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies STI-3031 - Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Withdrawn | Sorrento Therapeutics, Inc. | 2023-03-01 | 2023-05-01 | |
| Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma | Phase 1 | Terminated | Mayo Clinic | 3 | 2022-10-17 | 2025-12-03 |
| A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type IMC-001 - Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma | Phase 2 | Active not recruiting | ImmuneOncia Therapeutics Inc. | 23 | 2020-10-27 | 2026-09-24 |
| Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers IMC-001 - Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer | Phase 2 | Active not recruiting | Asan Medical Center | 48 | 2019-09-09 | 2026-05-22 |
| Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors IMC-001 - Solid Tumor, Metastasis | Phase 1 | Completed | ImmuneOncia Therapeutics Inc. | 15 | 2018-03-22 | 2020-05-28 |
Lymphoma, Extranodal NK-T-Cell (2) · Acute Coronary Syndrome (1) · Atherosclerosis (1) · Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Liver Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Peripheral (1) · Melanoma (1) · Neoplasm Metastasis (1) · Recurrence (1)
ImmuneOncia Therapeutics Inc. (3) · Asan Medical Center (1) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) · Mayo Clinic (1) · Sorrento Therapeutics, Inc. (1)
South Korea (4) · China (1) · United States (1)
Anastasios Dimou, MD (1) · Jun Pu, M.D. (1) · Won Seog Kim (1) · Yun Jeong Song, CMO/CEO (1)